Search for: cancer-survival
Article 1st International Conference on Machine Vision and Image Processing, MVIP 2020, 19 February 2020 through 20 February 2020 ; Volume 2020-February , 2020 ; Jamzad, M ; Sharif University of Technology
IEEE Computer Society 2020
Melanoma is the deadliest form of skin cancer if not treated early. The best way to cure melanoma is to treat it in its earliest stage of development. Since melanoma is similar to benign moles in its shape and appearance, it is often mistaken for moles and left untreated. Automatic melanoma detection is an essential way to increase the survival rate of patients by detecting melanoma in its early stages. In this paper, a new method for automatic diagnosis of melanoma using segmented dermatoscopic images is provided. Almost all related methods follow similar approaches but using different features. We have introduced several new features which could improve the accuracy of diagnosing melanoma....
The global burden of childhood and adolescent cancer in 2017: an analysis of the Global Burden of Disease Study 2017, Article The Lancet Oncology ; Volume 20, Issue 9 , 2019 , Pages 1211-1225 ; 14702045 (ISSN) ; Abdollahpour, I ; Advani, S.M ; Agius, D ; Ahmadian, E ; Alahdab, F ; Alam, T ; Alebel, A ; Alipour, V ; Allen, C.A ; Almasi Hashiani, A ; Alvarez, E.M ; Amini, S ; Amoako, Y.A ; Anber, N.H ; Arabloo, J ; Artaman, A ; Atique, S ; Awasthi, A ; Bagherzadeh, M ; Basaleem, H ; Bekru, E.T ; Bijani, A ; Bogale, K.A ; Car, M ; Carvalho, F ; Castro, C ; Catalá-López, F ; Chu, D.-T ; Costa, V.M ; Darwish, A.H ; Demeke, F.M ; Demis, A.B ; Demoz, G.T ; Dharmaratne, S.D ; Do, H.P ; Doan, L.P ; Dubey, M ; Eftekhari, A ; El-Khatib, Z ; Emamian, M.H ; Abbasalizad Farhangi, M ; Fernandes, E ; Fischer, F ; Fouladi Fard, R ; Friedrich, P.M ; Fukumoto, T ; Gedefaw, G.A ; Ghashghaee, A ; Gholamian, A ; Haj-Mirzaian, A ; Haj-Mirzaian, A ; Hamidi, S ; Harvey, J.D ; Hassen, H.Y ; Hay, S.I ; Hoang, C.L ; Hole, M.K ; Horita, N ; Hosseini, S.N ; Hosseinzadeh, M ; Hsairi, M ; Hudson, M.M ; Innos, K ; Jalilian, F ; James, S.L ; Kasaeian, A ; Kassa, T.D ; Kassebaum, N.J ; Keiyoro, P.N ; Khader, Y.S ; Khubchandani, J ; Kianipour, N ; Kirby, J ; Kisa, A ; Kisa, S ; Kocarnik, J.M ; Lauriola, P ; Lopez, A.D ; Mägi, M ; Malik, M.A ; Manafi, A ; Manafi, N ; Mansournia, M.A ; Massenburg, B.B ; Mehta, V ; Meles, H.G ; Meretoja, T.J ; Mestrovic, T ; Mirzaei Alavijeh, M ; Mir, S.M ; Mohammad, D.K ; Darwesh, A.M ; Mezerji, N.M.G ; Mohammadibakhsh, R ; Mohammadoo Khorasani, M ; Mokdad, A.H ; Moodley, Y ; Moosazadeh, M ; Moossavi, M ; Moradpour, F ; Morrison, S.D ; Muchie, K.F ; Naghavi, M ; Nazari, J ; Ngunjiri, J.W ; Nguyen, C.T ; Nguyen, L.H ; Nguyen, S.H ; Nguyen, T.H ; Nixon, M.R ; Olagunju, A.T ; Olagunju, T.O ; Ong, S.K ; Paapsi, K ; Pennini, A ; Pereira, D.M ; Pillay, J.D ; Qorbani, M ; Rabiee, M ; Rabiee, N ; Raoofi, S ; Rawaf, D.L ; Rawaf, S ; Reiner, R.C ; Rezaei, N ; Rezapour, A ; Roba, K.T ; Robison, L.L ; Rodriguez Galindo, C ; Roshandel, G ; Safiri, S ; Salahshoor, M ; Salehi Zahabi, S ; Samy, A.M ; Santric Milicevic, M.M ; Satpathy, M ; Sawyer, S.M ; Seyedmousavi, S ; Shabaninejad, H ; Shaikh, M.A ; Shamshirian, A ; Shamsizadeh, M ; Shirkoohi, R ; Siabani, S ; Singh, J.A ; Siramlee, K ; Tabarés-Seisdedos, R ; Temsah, M.-H ; Tran, B.X ; Ullah, I ; Vahedian Azimi, A ; Vollset, S.E ; Vos, T ; Waheed, Y ; Weldesamuel, G.T ; Workie, H.M ; Xu, R ; Yaseri, M ; Yonemoto, N ; Yu, C ; Zadnik, V ; Zahirian Moghadam, T ; Zaidi, Z ; Zangeneh, A ; Zewale, T.A ; Ziapour, A ; Zodpey, S ; Murray, C.J.L ; Fitzmaurice, C ; Bhakta, N ; GBD 2017 Childhood Cancer Collaborators ; Sharif University of Technology
Lancet Publishing Group 2019
Background: Accurate childhood cancer burden data are crucial for resource planning and health policy prioritisation. Model-based estimates are necessary because cancer surveillance data are scarce or non-existent in many countries. Although global incidence and mortality estimates are available, there are no previous analyses of the global burden of childhood cancer represented in disability-adjusted life-years (DALYs). Methods: Using the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2017 methodology, childhood (ages 0–19 years) cancer mortality was estimated by use of vital registration system data, verbal autopsy data, and population-based cancer registry incidence...
Article Breast Cancer: Targets and Therapy ; Volume 13 , 2021 , Pages 565-574 ; 11791314 (ISSN) ; Alshammari, F. O. F. O ; Youssef, A. M. M ; Al Tarawneh, F ; Al Sarayreh, S ; Almuhaisen, G. H ; Satari, A. O ; Al Shuneigat, J ; Alrawashdeh, H. M ; Sharif University of Technology
Dove Medical Press Ltd 2021
Purpose: Triple-negative breast cancer (TNBC) is characterized by high mortality rate, and its clinical management is difficult and complex. Therefore, there is a need for extensive efforts aimed at accelerating the discovery of novel therapies for TNBC. CYP4Z1 has been implicated in the development of breast cancer. The current study aimed at characterizing the expression of CYP4Z1 on TNBC. Materials and Methods: Using immunohistochemistry, CYP4Z1 expression was evaluated on 122 TNBC samples, four samples of breast cancers expressing ER, PR, and HER-2, and four samples of normal breast tissues. The association between the enzyme and various histopathological features and survival of...
Article Current Oncology ; Volume 28, Issue 5 , 2021 , Pages 3573-3584 ; 17187729 (ISSN) ; Alshammari, F. O. F. O ; Youssef, A. M. M ; Al Sarayra, Y. M ; Al Saraireh, R. A ; Al Muhaisen, G. H ; Al Mahdy, Y. S ; Al Kharabsheh, A. M ; Abufraijeh, S. M ; Al Rawashdeh, H. M ; Sharif University of Technology
Background: cervical cancer is one of the most common malignancies in women worldwide and its management remains challenging and complex. As Cytochrome4Z1 (CYP4Z1) is overex-pressed in many tumours, its expression in cervical cancer is unknown. Therefore, the present study aimed to evaluate CYP4Z1 expression in cervical cancers. Methods: CYP4Z1 expression was immunohistochemically assessed in 100 cases of cervical cancers along with ten normal cervix tissues, and the enzyme’s relationship to several clinicopathological features and survival was explored. Results: CYP4Z1 was strongly expressed in 55% of cervical cancer patients. Normal cervix samples were negative for CYP4Z1 expression....